BEIJING: As scientists around the world are racing against time to develop COVID-19 vaccines, vaccine safety should be seen as a priority in research and development.
China values safety in the process of vaccine development. Chinese researchers have tested vaccines on various animals before clinical trials. They’ve also got promising results on the vaccines’ safety and efficacy in phase-1 and phase-2 clinical trials and published the results in international journals, sharing information with the international community in an open, transparent, and responsible manner.
As phase-3 clinical trials are essential to evaluate the safety and efficacy of vaccines, China is ramping up efforts and pushing for international cooperation for its four vaccines that have entered phase-3 clinical trials. The phase-3 clinical trials in several countries in the Middle East, South America, and Southeast Asia are progressing smoothly.
The development of COVID-19 vaccines is a rigorous and complex procedure, facing uncertainties.
On Sept. 8, AstraZeneca and the University of Oxford temporarily halted worldwide phase-3 clinical trials of their vaccine, following an unexplained illness in one trial participant in Britain. Some of the clinical trials resumed after a safety investigation.–Agencies
